IRWD May 2024 5.000 call
| Previous close | 2.8000 |
| Open | 2.8000 |
| Bid | 3.0000 |
| Ask | 3.6000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.8000 - 2.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 8 |
ZacksEarnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to Decline
Ironwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireIronwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
BOSTON, May 01, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present new data from studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which patients are dependent on parenteral support (PS), during the 2024 Digestive Disease Week® (DDW) meeting. DDW is held from May 18-21, 2024, in Washington, D.C.
Business WireIronwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
BOSTON, April 25, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 9, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 3416473. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodp
